Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne (NASDAQ: TECH) has announced a quarterly dividend of $0.08 per share for the quarter ended June 30, 2025. The dividend will be payable on August 29, 2025, to shareholders of record as of August 18, 2025.

The company, a global life sciences leader providing innovative tools and bioactive reagents for research and clinical diagnostics, reported net sales of $1.2 billion in fiscal 2025 and employs approximately 3,100 people worldwide. Bio-Techne's products support scientific research into biological processes, disease progression, drug discovery, and clinical diagnostics.

Bio-Techne (NASDAQ: TECH) reported its Q4 and full-year fiscal 2025 results, with Q4 organic revenue growing 3% (4% reported) to $317.0 million. Full-year organic revenue increased 5% to $1.2 billion. The company reported Q4 GAAP EPS of $(0.11) versus $0.25 year-over-year, while adjusted EPS improved to $0.53 from $0.49.

The Protein Sciences segment showed strong performance with 4% organic growth (6% reported) in Q4. Notably, Bio-Techne announced the divestiture of its Exosome Diagnostics business, resulting in an $83.1 million impairment loss. The company's Q4 adjusted operating margin was 32.0%, down from 33.5% in the previous year, impacted by unfavorable product mix.

Bio-Techne (NASDAQ: TECH) has announced the divestiture of its Exosome Diagnostics business to Mdxhealth SA. The deal includes the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory, and related assets. Bio-Techne will maintain access to the proprietary exosome-based technology for kit development in its precision diagnostics segment.

Under the agreement terms, Bio-Techne will receive $5 million in MDXH stock plus future considerations. The transaction is expected to close in Q1 of Bio-Techne's fiscal 2026. The strategic move aims to strengthen Bio-Techne's focus on developing high-value products for life science research and clinical diagnostics markets while improving its operating margin profile.

ScaleReady (NYSE:TECH) has awarded a $100,000 G-Rex® Grant to Sidra Medicine, a women and children's hospital in Qatar. The grant will support the development of a CD19 CAR-T cell therapy product for pediatric oncology, including access to G-CART™ process and implementation of GMP-compliant production systems.

The grant is part of ScaleReady's broader initiative that has committed over $40 million in no-cost products to recipients. Recipients can receive up to $300,000 in individual grants and gain access to exclusive support from ScaleReady's consortium of G-Rex Grant Partners. Additionally, ScaleReady has launched a free LEAN Cell & Gene™ event series in partnership with Hanson Wade to promote efficient CGT manufacturing.

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady, has awarded $665,000 in G-Rex® Grants to three investigators at the University of Minnesota's Center for Genome Engineering.

The grants were distributed to: Dr. Branden Moriarity ($300,000) for CAR-NK cell therapy development for ovarian cancer, Dr. Beau Webber ($240,000) for TIL therapy development for solid tumors, and Dr. Joseph Skeate ($125,000) for T-cell therapy development targeting Batten Disease.

ScaleReady's G-Rex Grant Program has now exceeded $40M in no-cost product commitments. The company has also launched a new free program called LEAN Cell & Gene™ in partnership with Hanson Wade to promote efficient CGT manufacturing practices.

Bio-Techne (NASDAQ: TECH) has scheduled its fourth quarter and fiscal 2025 financial results conference call for August 6, 2025, at 8:00 a.m. CDT. The company will host both a conference call and webcast to discuss the results.

Investors can access the call through a toll-free number (1-800-274-8461) or international number (1-203-518-9814) using Conference ID: TECHQ4. A webcast will be available on the company's investor relations website. For those unable to attend live, a replay will be accessible until September 6, 2025, using Conference ID 11159590.

Bio-Techne (NASDAQ: TECH) has formed a strategic distribution partnership with Spear Bio to expand global access to SPEAR UltraDetect™ immunoassays, focusing initially on neurology research. This follows Bio-Techne's participation in Spear Bio's $45 million Series A funding in 2024.

The partnership leverages Spear Bio's Successive Proximity Extension Amplification Reaction (SPEAR) platform, which offers sensitivity 100-1000 times higher than current immunoassay platforms. The technology targets key biomarkers for neurodegenerative diseases, including pTau 231, pTau 217, GFAP, and Nf-L, with potential applications in inflammation and oncology.

Bio-Techne (NASDAQ: TECH) has announced a strategic partnership with Spear Bio to distribute next-generation ultrasensitive immunoassays for neurodegenerative disease research. The partnership follows Bio-Techne's participation in Spear Bio's $45 million Series A funding in 2024.

The collaboration will focus on distributing Spear Bio's SPEAR platform technology, which offers 2-3 orders of magnitude higher sensitivity than current immunoassay platforms. The initial offering targets key Alzheimer's disease biomarkers including pTau 217, GFAP, Nf-L, and pTau 231.

This partnership leverages Bio-Techne's global distribution network and immunoassay expertise with Spear Bio's ultrasensitive technology to advance early disease detection and therapeutic development.

Bio-Techne (NASDAQ: TECH) announced that its Simple Western™ Technology was instrumental in supporting the FDA approval of ZEVASKYN™, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics.

The Simple Western platform was chosen for its superior capabilities in detecting and quantifying Collagen VII, a critical protein for ZEVASKYN's potency testing. The technology's advantages include picogram-level sensitivity, reproducibility, and minimal sample requirements, making it essential for GMP-compliant lot release testing of both viral vector and cell therapy components.

The platform successfully overcame complex analytical challenges in standardization and assay development, particularly in evaluating Collagen VII's tertiary structure under non-denaturing conditions.